11:51 AM
Feb 14, 2018
 |  BC Extra  |  Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was down $4.01 (42%) to $5.45 on Wednesday after reporting that Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). The company said it is conducting further analysis of the data, but did not disclose next steps in the indication.

On the 50-patient trial's primary endpoint, once-daily 600 mg oral Aramchol did not significantly reduce liver fat content as measured by MRI proton density fat fraction (MRI-PDFF) from baseline to week 12 vs. placebo.

Aramchol is also in the Phase IIb ARREST trial to treat non-alcoholic steatohepatitis (NASH), for which data are expected next quarter. The product is a synthetic conjugate of cholic acid and arachidic acid.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD